Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) --...